ALKS Stock — Price, Charts & Analysis

Alkermes plc (ALKS) has a trailing P/E of 129.78x and a forward P/E of 26.27x. This places ALKS in a premium earnings multiple territory based on the valuation data currently available on Worldtickers.

ALKS trades with 129.78x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether ALKS looks overvalued or undervalued.

ALKS's P/E of 129.78x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

ALKS's trailing EPS is $0.37 and forward EPS is $1.83. Reported earnings growth is -99.40%, which helps show current profit momentum.

EPS, or earnings per share, shows how much profit Alkermes plc generated for each share. ALKS's trailing EPS is $0.37, and investors usually prefer EPS that is positive and growing over time.

Alkermes plc has a market cap of $8.06B, making ALKS a mid-cap stock based on the current market value shown on Worldtickers.

ALKS's latest stock price on Worldtickers is $48.02. The latest move is -$2.16 or -4.30%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

ALKS's quote includes a latest price of $48.02. The market open is $49.37. Previous close is $50.18. The intraday range is $47.93 to $49.86.

ALKS is down in the latest quote, with a move of -$2.16 or -4.30%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

ALKS generated $1.67B in trailing revenue. Revenue growth is 27.00%, which helps show whether demand is expanding or slowing.

ALKS's revenue growth is 27.00%, which is a strong demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

Yes, ALKS shows positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is $66.12M.

Gross margin is 87.18%. Margins show how efficiently Alkermes plc turns revenue into profit.

Alkermes plc carries $1.57B and holds $656.58M in cash.

ALKS holds $656.58M on its balance sheet.

ALKS's book value per share is $10.80.

Institutions hold 108.79% of ALKS shares. Insiders hold 1.40% of shares. Ownership mix helps investors understand how much of Alkermes plc is held by professional investors and company insiders.

ALKS has 167.76M shares outstanding. Float shares are 155.19M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for ALKS, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for ALKS is $1.83. Earnings growth is -99.40%. Revenue growth is 27.00%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

ALKS's trailing EPS is $0.37. Forward EPS is $1.83. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

ALKS is in the Healthcare sector. Its earnings multiple is 129.78x. Its latest displayed growth metric is 27.00%. Compare these figures with sector peers before deciding whether Alkermes plc is stronger or weaker than average.

ALKS trades at $48.02. The stock trades at 129.78x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Alkermes plc's fundamentals.

ALKS risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 0.27, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

ALKS should be compared with companies in Drug Manufacturers - Specialty & Generic. Its earnings multiple is 129.78x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Alkermes plc (ALKS) operates in Healthcare, specifically Drug Manufacturers - Specialty & Generic. Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed product

ALKS trades on NasdaqGS. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

ALKS stock is priced in USD on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Alkermes plc's official website listed on Worldtickers is investor.alkermes.com/phoenix.zhtml?c=92211&p=irol-irhome. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Alkermes plc employs about 2.05K people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Alkermes plc is headquartered in Dublin, Ireland. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

ALKS is in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

ALKS has traded between $25.17 and $55.67 over the past 52 weeks. At $48.02, it is 13.74% below the high and 90.78% above the low. The 52-week range helps gauge long-term price momentum.

ALKS is between its 50-day and 200-day moving averages, which suggests a mixed trend setup. Its 50-day moving average is $50.20 and its 200-day moving average is $36.79.

ALKS's RSI is 42.03. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

ALKS's latest RSI reading is 42.03, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for ALKS is near $47.66. Key resistance is near $53.88. Breaks above resistance or below support can change the short-term technical setup.

ALKS's nearest reported support level is $47.66. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

ALKS's nearest reported resistance level is $53.88. A breakout above resistance can improve momentum, especially when volume confirms the move.

ALKS trades about 2.07M shares daily on average. The latest displayed volume is 1.64M shares. Volume helps show liquidity and whether trading interest is unusually high or low.

ALKS's MACD is -0.15, which is a negative momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

ALKS is between its 50-day and 200-day moving averages, which suggests a mixed trend setup. RSI is 42.03 (neutral). MACD is bearish. Nearest support is around $47.66. Resistance is around $53.88. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is $49.74 (-3.45% from price). MA50 is $50.20 (-4.34% from price). MA200 is $36.79 (30.51% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. ALKS's MA20 is $49.74. MA50 is $50.20. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

ALKS's pivot is near $50.52. Support is near $47.66. Resistance is near $53.88. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for ALKS is near $44.57. The next upper resistance zone is near $50.77. These levels help define risk and possible follow-through zones after a breakout or breakdown.

ALKS's Bollinger range is roughly $47.34 to $52.14. Band width is near 9.65%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

ALKS's ATR-based typical daily range is about 3.75%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 1.64M shares. Average volume is about 2.07M shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

ALKS's all-time high shown on Worldtickers is $98.50. Its all-time low is $0.94. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

ALKS has a beta of 0.27, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.